Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate co-infusion to prevent anti-adalimumab immunization in spondyloarthritis
2019-004088-34Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of adalimumab in axial spondyloarthritis (axSpA), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Anti-adalimumab antibodies at 6 months. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2019-004088-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004088-34.